ATE536185T1 - Verfahren zur abschwächung von reaktionen auf hautreizende mittel - Google Patents

Verfahren zur abschwächung von reaktionen auf hautreizende mittel

Info

Publication number
ATE536185T1
ATE536185T1 AT02723627T AT02723627T ATE536185T1 AT E536185 T1 ATE536185 T1 AT E536185T1 AT 02723627 T AT02723627 T AT 02723627T AT 02723627 T AT02723627 T AT 02723627T AT E536185 T1 ATE536185 T1 AT E536185T1
Authority
AT
Austria
Prior art keywords
immune responses
compositions
cd1d
attenuate
reactions
Prior art date
Application number
AT02723627T
Other languages
English (en)
Inventor
S Wilson
Glenn Dranoff
Silke Gillessen
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE536185T1 publication Critical patent/ATE536185T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
AT02723627T 2001-03-26 2002-03-26 Verfahren zur abschwächung von reaktionen auf hautreizende mittel ATE536185T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27883701P 2001-03-26 2001-03-26
PCT/US2002/009378 WO2002076401A2 (en) 2001-03-26 2002-03-26 Method of attenuating reactions to skin irritants

Publications (1)

Publication Number Publication Date
ATE536185T1 true ATE536185T1 (de) 2011-12-15

Family

ID=23066584

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02723627T ATE536185T1 (de) 2001-03-26 2002-03-26 Verfahren zur abschwächung von reaktionen auf hautreizende mittel

Country Status (6)

Country Link
US (4) US7419958B2 (de)
EP (1) EP1372668B1 (de)
AT (1) ATE536185T1 (de)
AU (1) AU2002254396A1 (de)
CA (1) CA2441893C (de)
WO (1) WO2002076401A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051156A1 (en) * 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US7419958B2 (en) * 2001-03-26 2008-09-02 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
MXPA05002292A (es) * 2002-08-27 2006-05-22 Nestle Sa Prevencion de tratamiento de tejido epitelial o perdida de pelo.
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8232304B2 (en) * 2002-10-24 2012-07-31 G & R Pharmaceuticals, Llc Antifungal formulations
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US10117812B2 (en) * 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1812015B1 (de) * 2004-11-02 2012-01-04 The Board of Trustees of Leland Stanford Junior University Verfahren zur hemmung von nkt-zellen
US20070042026A1 (en) * 2005-03-17 2007-02-22 Wille John J Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
US8372040B2 (en) 2005-05-24 2013-02-12 Chrono Therapeutics, Inc. Portable drug delivery device including a detachable and replaceable administration or dosing element
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
WO2008100912A1 (en) * 2007-02-12 2008-08-21 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
EP2242476A2 (de) 2008-01-14 2010-10-27 Foamix Ltd. Aufschäumbare pharmazeutische poloxamer-zusammensetzungen mit wirkstoffen und/oder therapeutischen zellen und verwendungen
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
EP2723347B1 (de) 2011-06-24 2019-09-04 GRI Bio, Inc. Vorbeugung und behandlung entzündlicher erkrankungen
EP2729148A4 (de) 2011-07-06 2015-04-22 Parkinson S Inst Zusammensetzungen und verfahren zur behandlung von symptomen bei patienten mit morbus parkinson
US20140221320A1 (en) * 2011-07-08 2014-08-07 The Research Foundation For The State University Of New York Topical minocycline ointment for suppression of allergic skin responses
JP6185575B2 (ja) * 2012-06-05 2017-08-23 オラテック セラピューティクス リミティド ライアビリティ カンパニー 皮膚炎症性疾患の治療方法
US8663177B1 (en) * 2012-09-28 2014-03-04 Anal-Gesic LLC Medication delivery, dosing and safety devices, systems and kits
US10329315B2 (en) 2012-10-12 2019-06-25 The Brigham And Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
JP6743051B2 (ja) 2015-01-27 2020-08-19 ラヴァ・セラピューティクス・ベー・フェー Ｃｄ１ｄを標的とする単一ドメイン抗体
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
JP2018511127A (ja) 2015-03-12 2018-04-19 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 渇望入力及び支援システム
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
EP3565617A1 (de) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Vorrichtungen und verfahren zur transdermalen wirkstofffreisetzung
CN116439916A (zh) * 2017-09-21 2023-07-18 宝洁公司 吸收制品
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
CA3113409A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
US11938004B2 (en) 2019-05-31 2024-03-26 The Procter & Gamble Company Absorbent article having a waist gasketing element
EP4054497B1 (de) 2019-11-04 2023-11-01 The Procter & Gamble Company Verfahren zum verbinden von elastischen teilen unter spannung auf einen vorschubträger
CN115484908A (zh) 2020-05-05 2022-12-16 宝洁公司 包括具有不同拉伸特性的前腰片和后腰片的吸收制品
JP7525644B2 (ja) 2020-05-05 2024-07-30 ザ プロクター アンド ギャンブル カンパニー 改良された弾性パネルを含む吸収性物品

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174912A3 (de) * 1984-09-13 1986-06-04 Ciba-Geigy Ag Phosphorverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung
JPS63255213A (ja) 1987-04-13 1988-10-21 Kanebo Ltd 養毛化粧料
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
JPH0317020A (ja) 1989-06-14 1991-01-25 Nippon Koutai Kenkyusho:Kk 抗ｈｉｖ剤
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5705187A (en) 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5565207A (en) * 1990-09-19 1996-10-15 Pola Kasei Kogyo Kabushiki Kaisha Scalp moisturizer and external skin preparation
US5602183A (en) 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
WO1992017189A1 (en) 1991-03-29 1992-10-15 The Regents Of The University Of California Gangliosides with immunosuppressive activity
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
JP3231079B2 (ja) * 1992-05-29 2001-11-19 ポーラ化成工業株式会社 消炎鎮痛外用剤
US7063844B2 (en) * 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
EP0751780B1 (de) 1993-06-21 2003-09-03 Brigham And Women's Hospital Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5459037A (en) 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
JP2896321B2 (ja) 1994-10-27 1999-05-31 鐘紡株式会社 β−グルコセレブロシダーゼの活性化方法
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
US5738856A (en) * 1995-11-03 1998-04-14 Ocular Research Of Boston, Inc. Skin care preparation and method
FR2742054B1 (fr) * 1995-12-06 1998-01-09 Synthelabo Compositions pharmaceutiques contenant un agent anti-inflammatoire et des ceramides vegetales
US5776683A (en) 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
SK283518B6 (sk) * 1996-10-15 2003-08-05 The Liposome Company, Inc. Konjugát peptidu s lipidom, lipozóm, farmaceutický prostriedok a použitie
CN1222293C (zh) * 1997-04-10 2005-10-12 麒麟麦酒株式会社 含有α－糖基神经酰胺的NKT细胞活化剂
US6063387A (en) * 1997-04-17 2000-05-16 Elizabeth Arden Co., Division Of Conopco, Inc. Anhydrous cosmetic composition with ceramides for firming skin
FR2765877B1 (fr) * 1997-07-10 1999-09-10 Oreal Composition comprenant une dispersion aqueuse de vesicules lipidiques a base de carbamates a chaine cholesteryle, utilisation notamment en cosmetique et nouveaux composes
WO1999012562A1 (en) * 1997-09-12 1999-03-18 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
TW575420B (en) 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
JP2001510487A (ja) 1997-12-05 2001-07-31 デーエスエム ナムローゼ フェンノートシャップ 遊離スフィンゴイド塩基及びセラミドの組合せを含む組成物並びにその使用
CA2316041A1 (en) 1997-12-30 1999-07-08 Pam Fredman Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
US6610835B1 (en) 1998-02-12 2003-08-26 Emory University Sphingolipid derivatives and their methods of use
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
JPH11302155A (ja) * 1998-04-24 1999-11-02 La Shinshia Kk アトピー性皮膚炎のための皮膚外用剤
CA2333750A1 (en) 1998-06-23 1999-12-29 Dale T. Umetsu Adjuvant therapy
JP2003524146A (ja) 1998-07-09 2003-08-12 ニッコロフ，ブライアン・ジェイ Ｔ細胞上のナチュラルキラーレセプターとそれらに対応するリガンドとの相互作用を変調することにより疾患を治療する方法
DE19841794A1 (de) 1998-09-12 2000-03-16 Beiersdorf Ag Kombinationen von Antiadhäsiva (Ceramide und Sphingosine und Derivate) und Mikrobiziden
JP2000264825A (ja) * 1999-03-17 2000-09-26 Fancl Corp 乳化組成物
JP2000264829A (ja) * 1999-03-17 2000-09-26 Fancl Corp 乳化組成物
US20010051156A1 (en) * 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
AU2002213588A1 (en) 2000-06-05 2001-12-17 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
KR20030032961A (ko) 2000-06-06 2003-04-26 기린 비루 가부시키가이샤 내츄럴 킬러 ｔ 세포의 증폭 방법
DK2336187T3 (en) 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
AU2001268564A1 (en) 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
JP3986957B2 (ja) 2000-08-18 2007-10-03 三菱電機株式会社 ランプ用トランス
DE10046658A1 (de) 2000-09-20 2002-04-04 Bosch Gmbh Robert Induktiver Übertrager und ein Verfahren zu dessen Herstellung
US6372236B1 (en) * 2000-10-18 2002-04-16 Doosan Corporation Cream composition for skin care
JP3523245B1 (ja) * 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
IL140537A0 (en) 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
US7419958B2 (en) * 2001-03-26 2008-09-02 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US6662434B2 (en) 2001-04-03 2003-12-16 General Electric Company Method and apparatus for magnetizing a permanent magnet
EP1385501A2 (de) 2001-04-11 2004-02-04 Atherogenics, Inc. Probucol-monoesters und ihre verwendung zur erhöhung des hdl-plasmaspiegels und zur verbesserung der hdl-funktionalität
US20020171538A1 (en) 2001-05-15 2002-11-21 Kuo-Hsin Su Vehicle motion detector and control device arrangement
US20020171557A1 (en) 2001-05-18 2002-11-21 Wegener William E. Security electronic system
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US20030147865A1 (en) 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
WO2003092615A2 (en) 2002-05-01 2003-11-13 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
AU2003251518B2 (en) * 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
ES2384439T3 (es) 2002-06-14 2012-07-04 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procedimientos de tratamiento y prevención de colitis que se implican IL-13 y células NK-T
US7368142B2 (en) 2002-08-01 2008-05-06 Renew Life Formulas, Inc. Natural sweetener
MXPA05002292A (es) 2002-08-27 2006-05-22 Nestle Sa Prevencion de tratamiento de tejido epitelial o perdida de pelo.
KR20050062551A (ko) * 2002-09-20 2005-06-23 기린 비루 가부시키가이샤 α-글리코실세라미드를 유효 성분으로 하는 Ｃ형 간염 바이러스 억제제
CA2500478A1 (en) 2002-09-27 2004-04-08 Biomira, Inc. Glycosylceramide analogues
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040235162A1 (en) 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
US20050032210A1 (en) 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
CA2519568C (en) 2003-03-20 2012-01-03 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
WO2004084874A2 (en) 2003-03-24 2004-10-07 Brigham And Women's Hospital, Inc. Mtp inhibitors for inhibiting inflammation
WO2005014008A2 (en) 2003-07-17 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of disorders associated with natural killer t cells
KR101215808B1 (ko) * 2004-06-11 2012-12-26 도꾸리쯔교세이호징 리가가쿠 겐큐소 조절성 세포 리간드를 리포좀에 함유시켜 이루어지는 의약
WO2006002132A2 (en) 2004-06-21 2006-01-05 Exxonmobil Chemical Patents Inc. Olefin polymerization process
EP1812015B1 (de) 2004-11-02 2012-01-04 The Board of Trustees of Leland Stanford Junior University Verfahren zur hemmung von nkt-zellen
US20080241174A1 (en) 2005-03-18 2008-10-02 The Board Of Trustees Of The Leland Stanford Junior University Production And Therapeutic Uses Of Th1-Like Regulatory T Cells
JP5331049B2 (ja) 2010-04-16 2013-10-30 株式会社日立製作所 回転電機の回転子挿入装置および挿入方法

Also Published As

Publication number Publication date
US20140286949A1 (en) 2014-09-25
US20080260680A1 (en) 2008-10-23
AU2002254396A1 (en) 2002-10-08
WO2002076401A3 (en) 2003-02-27
EP1372668A2 (de) 2004-01-02
EP1372668B1 (de) 2011-12-07
US20020165170A1 (en) 2002-11-07
US7419958B2 (en) 2008-09-02
CA2441893A1 (en) 2002-10-03
US10226476B2 (en) 2019-03-12
CA2441893C (en) 2015-01-20
US20160074423A1 (en) 2016-03-17
WO2002076401A2 (en) 2002-10-03
EP1372668A4 (de) 2007-07-25

Similar Documents

Publication Publication Date Title
ATE536185T1 (de) Verfahren zur abschwächung von reaktionen auf hautreizende mittel
DE60229971D1 (de) Zubereitungen zur reizhemmenden rosacea-behandlung
BRPI0407993A (pt) inibidores de p38 e métodos para uso dos mesmos
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
HUP0102899A2 (hu) Eljárás gyulladásgátló, különösen fertőtlenítő hatású és/vagy sebgyógyulást elősegítő szerek alsó légutakba történő beadására szolgáló készítmények előállítására
ATE443523T1 (de) Verfahren zur behandlung von gelenkentzündung, schmerzen und mobilitätsverlust
ES2135470T3 (es) Composiciones farmaceuticas y metodos que usan ibobutiramida para tratar trastornos de betaglobina.
PT781281E (pt) Derivados de beta-carbolina agonistas da melatonina seu processo de preparacao e sua utilizacao a titulo de medicamento
DE3752007D1 (de) Mittel zur Entziehung von Endprodukten der fortgeschrittenen Glycosylation
DK0759740T3 (da) Anvendelse af laminarin og oligosaccharider afledt af laminarin inden for kosmetologien og til fremstilling af et medikament beregnet til behandling af huden
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
CA2182030A1 (fr) Utilisation d'un antagoniste de bradykinine dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
FR2755965B1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
DK461689D0 (da) Anvendelse af aktive stoffer med seritoninagonistisk virkning til fremstilling af laegemidler med apoplexia cerebri
ATE318610T1 (de) Orale zusammensetzungen zur behandlung von kopfhauterkrankungen
ATE77230T1 (de) Melatoninhaltige mittel sowie deren verwendungen.
BR0211936A (pt) Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos
MXPA03011622A (es) Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas.
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
JP2004514689A (ja) 表面血流刺激性スキンクリーム
PT93813A (pt) Processo para a preparacao de um produto para o tratamento das unhas, da pele e dos cabelos, contendo trigonelina e vitamina b6
DE60129606D1 (de) Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie
CY1109393T1 (el) Η χρηση κιγχονης για την παρασκευη ενος φαρμακου που διεγειρει την αγγειογενεση
DK1492539T3 (da) Statin-terapi til forögelse af kognitiv funktion
US20110052719A1 (en) Dermatological composition that can be used in particular for the care and prevention of eschars